As PTGDS was demonstrated to regulate MYH9 and Wnt–β-catenin–STAT3 axis, further investigations are needed to explore the therapeutic effect of combination therapy among AT56, WP1066, Blebbistatin, and Wnt–β-catenin-targeted agents in DLBCL treatment. Here, STAT3 is linked to diffuse large B-cell lymphoma.